Tuesday, June 04, 2019 9:44:13 PM
Perfect example Lykiri, thank you.
You see practicing physicians often have difficulty with these restrictions that are enforced upon drug and drug companies.They’re just not used to talking to their peers that way, and really they don’t have to except when talking on behalf of Northwest Biotherapeutics. The precarious position as the PI is that it is impossible for her not to speak of DC Vax without doing it on behalf of Northwest biotherapeutics. That balance and the tight rope is just not what they are used to at all. They are trained to project confidence in their decisions and opinions and not to worry about their mistakes. However it is clear to me that Linda Liau has been coached now multiple times by industry lawyers on what she can and cannot say. She is in a very special place because she is the overall PI and has a vested financial interest in the development and success of this product. She is very concerned of risk. You can tell this when you hear her speak about DC VAX Outside of a scientific conference. Her pacechanges she starts to correct her self and is not at all as confident in her wording.
If only management were as careful as her during this heightened period of risk.
You see practicing physicians often have difficulty with these restrictions that are enforced upon drug and drug companies.They’re just not used to talking to their peers that way, and really they don’t have to except when talking on behalf of Northwest Biotherapeutics. The precarious position as the PI is that it is impossible for her not to speak of DC Vax without doing it on behalf of Northwest biotherapeutics. That balance and the tight rope is just not what they are used to at all. They are trained to project confidence in their decisions and opinions and not to worry about their mistakes. However it is clear to me that Linda Liau has been coached now multiple times by industry lawyers on what she can and cannot say. She is in a very special place because she is the overall PI and has a vested financial interest in the development and success of this product. She is very concerned of risk. You can tell this when you hear her speak about DC VAX Outside of a scientific conference. Her pacechanges she starts to correct her self and is not at all as confident in her wording.
If only management were as careful as her during this heightened period of risk.
Recent NWBO News
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • InvestorsHub NewsWire • 05/11/2026 01:00:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • GlobeNewswire Inc. • 05/11/2026 12:30:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:38:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
